Banque Soria Ester 4

What Happened Banque Soria Ester, Moderna’s (MRNA) Chief Commercial Officer, received two equity awards on July 5, 2026: 18,658 derivative shares (stock options) and 38,364 restricted stock units (RSUs). Both grants are reported at $0 acquisition price (typical for awards) and therefore show $0 cash outlay at grant. These are awards (not open-market purchases or sales) and are part of compensation rather than immediate trades.

Key Details

• Transaction date(s) and price(s): Grants dated July 5, 2026; both reported at $0.00 per share.
• Award types and quantities: 18,658 (options/derivative award) and 38,364 RSUs (convert 1-for-1 to common stock).
• Vesting: 25% of each award vests on July 5, 2027; the remainder vests in twelve equal quarterly installments thereafter (per filing footnotes).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 filed July 7, 2026 reporting the July 5, 2026 grants — appears timely (no late-filing flag shown).
• Footnotes of note: F1 describes the option vesting schedule; F2 confirms RSUs convert one-for-one to common stock; F3 repeats the RSU vesting schedule.

Context These grants are standard executive compensation (options + RSUs) and do not involve a market purchase or sale. Options will become exercisable as they vest; RSUs convert into common shares on a one‑for‑one basis as they vest. Such awards typically depend on continued employment and do not alone indicate immediate insider buying/selling intent.